Associated Genetic Biomarkers
FGFR3 A391E is present in 0.02% of AACR GENIE cases, with bladder urothelial carcinoma having the greatest prevalence .
FGFR3 A391E serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 A391E as an inclusion criterion, 1 is phase 3 (1 open).
Trials with FGFR3 A391E in the inclusion eligibility criteria most commonly target urothelial carcinoma .
Infigratinib and placebo are the most frequent therapies in trials with FGFR3 A391E as an inclusion criteria .
Significance of FGFR3 A391E in Diseases
Urothelial Carcinoma +
FGFR3 is altered in 27.83% of urothelial carcinoma patients with FGFR3 A391E present in 0.1% of all urothelial carcinoma patients .
FGFR3 A391E is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 A391E and urothelial carcinoma as inclusion criteria, 1 is phase 3 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.